Table 1. Descriptive Statistics of Patient Characteristics and Univariate Logistic Regression.
| Characteristic | All patients, No. (%) (n = 2955) | BP status, No. (%) | Firth bias-reduced penalized-likelihood logistic regression | ||
|---|---|---|---|---|---|
| No BP (n = 2920) | BP (n = 35) | OR (95% CI) | Univariate P value | ||
| Age at first ICI cycle, y | |||||
| <70 | 1892 (64.0) | 1877 (64.3) | 15 (42.9) | 1 [Reference] | .01 |
| ≥70 | 1063 (36.0) | 1043 (35.7) | 20 (57.1) | 2.38 (1.23-4.70) | |
| Sex | |||||
| Male | 1632 (55.2) | 1607 (55.0) | 25 (71.4) | 1.98 (0.99-4.27) | .05 |
| Female | 1323 (44.8) | 1313 (45.0) | 10 (28.6) | 1 [Reference] | |
| ICI agent | |||||
| Atezolizumab | 153 (5.2) | 153 (5.2) | 0 | NA | NAa |
| Avelumab | 17 (0.6) | 17 (0.6) | 0 | ||
| Cemiplimab | 22 (0.7) | 22 (0.8) | 0 | ||
| Durvalumab | 78 (2.6) | 78 (2.7) | 0 | ||
| Ipilimumab | 35 (1.2) | 35 (1.2) | 0 | ||
| Nivolumab | 1055 (35.7) | 1041 (35.7) | 14 (40.0) | ||
| Nivolumab + ipilimumab | 190 (6.4) | 188 (6.4) | 2 (5.7) | ||
| Pembrolizumab | 1405 (47.5) | 1386 (47.5) | 19 (54.3) | ||
| Immunotherapy type | |||||
| CTLA-4 | 35 (1.2) | 35 (1.2) | 0 | 1 [Reference] | .30a |
| PD-1 | 2482 (84.0) | 2449 (83.9) | 33 (94.3) | 0.97 (0.13-123.78) | |
| PD-1 and CTLA-4 | 190 (6.4) | 188 (6.4) | 2 (5.7) | 0.94 (0.07-130.95) | |
| PD-L1 | 248 (8.4) | 248 (8.5) | 0 | 0.14 (0-26.55) | |
| Cancer type (organ) | |||||
| Nonskin cancerb,c | 2375 (80.4) | 2357 (80.7) | 18 (51.4) | 1 [Reference] | <.01 |
| Melanoma | 505 (17.1) | 493 (16.9) | 12 (34.3) | 3.23 (1.53-6.60) | |
| Nonmelanoma skin cancerd,e | 75 (2.5) | 70 (2.4) | 5 (14.3) | 9.94 (3.38-24.98) | |
| Epithelial tumor origin | |||||
| Epithelial tumors | 2836 (96.0) | 2801 (95.9) | 35 (100) | 1 [Reference] | .35 |
| Nonepithelial tumorsf | 119 (4.0) | 119 (4.1) | 0 | 0.33 (0-2.35) | |
Abbreviations: BP, bullous pemphigoid; CTLA-4, cytotoxic T-lymphocyte–associated protein 4; ICI, immune checkpoint inhibitor; NA, not applicable; OR, odds ratio; PD-1, programmed cell death 1 protein; PD-L1, programmed cell death 1 ligand 1.
Given the large number of ICI agent groups, the P value for ICI agent was calculated among pooled groups by molecular target.
Nonskin cancers in the no BP group that made up greater than 1.0% of the total sample (2357) included lung cancer (1218 [51.7%]), renal cancer (219 [9.3%]), bladder or urothelial cancer (193 [8.2%]), head and neck carcinomas (177 [7.5%]), gastrointestinal malignant tumors (155 [6.6%]), brain or central nervous system tumors (74 [3.1%]), lymphoma in lymph nodes (50 [2.1%]), breast cancer (46 [2.0%]), liver cancer (44 [1.9%]), and cervical or uterine carcinoma (38 [1.6%]).
Nonskin cancers in the BP group (18) included lung cancer (8 [44.4%]), renal cancer (3 [16.7%]), bladder or urothelial cancer (2 [11.1%]), esophageal cancer (1 [5.6%]), prostate cancer (1 [5.6%]), colon cancer (1 [5.6%]), breast cancer (1 [5.6%]), and salivary gland cancer (1 [5.6%]).
Nonmelanoma skin cancers in the no BP group (70) included Merkel cell carcinoma (35 [50.0%]), squamous cell carcinoma (34 [48.6%]), and basal cell carcinoma (1 [1.4%]).
Nonmelanoma skin cancers in the BP group (35) included squamous cell carcinoma (4 [11.4%]) and basal cell carcinoma (1 [2.9%]).
Nonepithelial tumors in the no BP group (119) included diffuse large B-cell lymphoma (36 [30.3%]), Hodgkin lymphoma (27 [22.7%]), acute myeloid leukemia (8 [6.7%]), chronic lymphocytic leukemia (6 [5.0%]), leiomyosarcoma (5 [4.2%]), B-cell lymphoma, not otherwise specified (4 [3.4%]), multiple myeloma (4 [3.4%]), follicular lymphoma (3 [2.5%]), liposarcoma (3 [2.5%]), lymphoma, not otherwise specified (3 [2.5%]), sarcoma, not otherwise specified (3 [2.5%]), angiosarcoma (2 [1.7%]), pleomorphic cell sarcoma (2 [1.7%]), primary mediastinal (thymic) large B-cell lymphoma (2 [1.7%]), spindle cell sarcoma (2 [1.7%]), Ewing sarcoma (1 [0.8%]), follicular dendritic cell sarcoma (1 [0.8%]), gliosarcoma (1 [0.8%]), mucosa-associated lymphoid tissue lymphoma (1 [0.8%]), mantle cell lymphoma (1 [0.8%]), natural killer cell leukemia (1 [0.8%]), prolymphocytic T-cell leukemia (1 [0.8%]), rhabdomyosarcoma (1 [0.8%]), and therapy-related myeloid neoplasm, not otherwise specified (1 [0.8%]).